

Fact sheet references

- Das RR, Panigrahi I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: A systematic review. *PLoS One*. 2014;9(9):e106629.
- Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A, et al. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: A systematic review and meta-analysis. *Lancet Infect Dis*. 2018;18(4):461-72.
- Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial. *JAMA*. 2012;307(6):573-82.
- Hong E, Terrade A, Taha M-K. Immunogenicity and safety among laboratory workers vaccinated with Bexsero vaccine. *Hum Vaccin Immunother*. 2017;13(3):645-8.
- Institute of Environmental Science and Research Ltd. Meningococcal disease quarterly report Jan - Dec 2019. Porirua: Institute of Environmental Science and Research Ltd (ESR); 2020.
- Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age - A phase 3 extension to a randomised controlled trial. *Vaccine*. 2017;35(2):395-402.
- Jackson C, Yarwood J, Saliba V, Bedford H. UK parents' attitudes towards meningococcal group B (MenB) vaccination: A qualitative analysis. *BMJ open*. 2017;7(4):e012851.
- Kanabar DJ. A clinical and safety review of paracetamol and ibuprofen in children. *Inflammopharmacology*. 2017;25(1):1-9.
- Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. *Clin Vaccine Immunol*. 2011;18(3):483-6.
- Lopez L, Sherwood J. The epidemiology of meningococcal disease in New Zealand 2013. Wellington: Institute of Environmental Science and Research Ltd (ESR); 2014. Report No.: FW14023.
- Martinon-Torres F, Safadi MAP, Martinez AC, Marquez PI, Torres JCT, Weckx LY, et al. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial. *Vaccine*. 2017;35(28):3548-57.
- Martinon-Torres F, Carmona Martinez A, Simko R, Marquez PI, Arimany J-L, Gimenez-Sanchez F, et al. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial. *J Infect*. 2018;76(3):258-69.
- Medsafe. New Zealand data sheet: Bexsero [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2018 [updated 2020 March 31; cited 2020 June 26]. Available from: <https://www.medsafe.govt.nz/profs/Datasheet/b/bexseroinj.pdf>
- Nokleby H. Vaccination and anaphylaxis. *Curr Allergy Asthma Rep*. 2006;6(1):9-13.
- Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: A national observational cohort study. *Lancet*. 2016;388(10061):2775-82.
- Peterson ME, Mile R, Li Y, Nair H, Kyaw MH. Meningococcal carriage in high-risk settings: A systematic review. *Int J Infect Dis*. 2018;73:109-17.
- Pharmaceutical Management Agency (PHARMAC). Pharmaceutical Schedule [Internet]. Wellington: PHARMAC; 2021 [updated 2021 July 1; cited 2021 July 1]. Available from: <https://pharmac.govt.nz/pharmaceutical-schedule/community-section-b/>
- Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: Two open-label, randomised controlled trials. *Lancet*. 2009;374:1339-50.
- Prymula R, Habib A, François N, Borys D, Schuerman L. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. *Vaccine*. 2013;31(16):2080-8.
- Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. *Hum Vaccin Immunother*. 2014;10(7):1993-2004.
- Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials. *Lancet*. 2013;381(9869):825-35.
- Watson PS, Turner DPJ. Clinical experience with the meningococcal B vaccine, Bexsero: Prospects for reducing the burden of meningococcal serogroup B disease. *Vaccine*. 2016;34(7):875-80.
- Wysocki J, Center KJ, Brzostek J, Majda-Stanislawski E, Szymanski H, Szenborn L, et al. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. *Vaccine*. 2017;35(15):1926-35.